Mind Medicine Newsroom

Mind Medicine Price Target Announced at $20.00/Share by Chardan Capital

Dow JonesDec 20, 2024 19:27

Mind Medicine Initiated at Buy by Chardan Capital

Dow JonesDec 20, 2024 19:27

Mind Medicine Analyst Ratings

BenzingaDec 18, 2024 00:12

Oppenheimer Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $20

Futu NewsDec 17, 2024 21:33

Mind Medicine (MNMD) Receives a Buy From Oppenheimer

TipRanksDec 17, 2024 20:48

RBC Capital Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $21

Futu NewsNov 20, 2024 23:31

RBC Capital Remains a Buy on Mind Medicine (MNMD)

TipRanksNov 20, 2024 23:16

Mind Medicine Analyst Ratings

BenzingaNov 11, 2024 18:20

Maxim Group Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $18

Futu NewsNov 10, 2024 01:32

Oppenheimer Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $20

Futu NewsNov 10, 2024 00:31

H.C. Wainwright Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $55

Futu NewsNov 10, 2024 00:31

Mind Medicine's Strategic Advancements and Clinical Progress Drive Buy Rating

TipRanksNov 9, 2024 01:19

CCORF Maintains Mind Medicine(MNMD.US) With Buy Rating, Raises Target Price to $16

Futu NewsNov 8, 2024 21:32

RBC Capital Maintains Mind Medicine(MNMD.US) With Buy Rating, Cuts Target Price to $21

Futu NewsNov 8, 2024 20:35

Analysts Offer Insights on Healthcare Companies: Mind Medicine (MNMD), Knight Therapeutics (OtherKHTRF) and OnKure Therapeutics (OKUR)

TipRanksNov 8, 2024 20:12

RBC Capital Keeps Their Buy Rating on Mind Medicine (MNMD)

TipRanksNov 8, 2024 20:12

Leerink Partners Initiates Mind Medicine(MNMD.US) With Buy Rating, Announces Target Price $20

Futu NewsOct 12, 2024 06:31

Mind Medicine Is Maintained at Buy by Canaccord Genuity

Dow JonesSep 16, 2024 22:29

Mind Medicine Analyst Ratings

BenzingaAug 29, 2024 20:04

HC Wainwright & Co. Maintains Buy on Mind Medicine, Raises Price Target to $55

BenzingaAug 29, 2024 20:04